We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT05298423
Brief Title: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

First Submitted : March 17, 2022
First Submitted that Met QC Criteria : March 17, 2022
First Posted : March 28, 2022

Last Update Submitted that Met QC Criteria : September 9, 2022
Last Update Posted : September 10, 2022